Ascendiant yesterday raised the firm’s price target on Outlook Therapeutics to $2 from $1.50 and keeps a Buy rating on the shares. The company reported in-line Q4 results and remains on track for an ONS-5010 FDA application re-submission by the end of 2024, the analyst tells investors in a research note. The firm believes an FDA approval for ONS-5010 is still likely and that the current “depressed share price is not reflective of that and represents significant upside potential.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OTLK:
- Gracell downgrade, Fusion upgrade: Wall Street’s top analyst calls
- Outlook Therapeutics upgraded at Capital One after ‘great feedback’ from FDA
- Outlook Therapeutics upgraded to Overweight from Equalweight at Capital One
- Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU
- Outlook Therapeutics expects to resubmit ONS-5010 BLA by end of 2024